Clinical Trials Browser

Phase 2 × rilotumumab × Gynecologic × Clear all

NCT01039207 2017-09-07

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Completed

31 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms